Abstract: Intermediates useful for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines, which are themselves useful as inhibitors of signal transduction mediated by tyrosine kinases. The intermediates of the invention are 2-chloro-4,6-diamino-7,8-dihydropyrimido[5,4-d]pyrimidines, protected and unprotected 4-amino-2,6-dichloro-7,8-dihydropyrimido[5,4-d]pyrimidines and 4-amino-2,6,8-trichloropyrimido[5,4-d]pyrimidines.

Abstract: Indolinones of general formula I 1

Abstract: Indolinones of general formula I 1

Abstract: A system for testing systems which are in turn used to test the leaktightness of a hollow body is suggested. Instead of the hollow body, a test body (2) is placed in the system which generates a defined pressure increase in a measuring chamber (4) within a pre-determined time span. This defined pressure increase corresponds exactly to the pressure increase generated by a hollow body with a small amount of leakage, wherein the hollow body can still just be regarded as leaktight. The test body can be configured as a glass capillary which extends in a sealing manner between two chambers with different air pressure. Alternatively, the test body can comprise a material which can accept a defined amount of moisture from the ambient atmosphere during storage. A vacuum formed around the test body causes moisture to be withdrawn from the test body and at least partially evaporated in the vacuum, which again leads to an increase in pressure in the chamber.

Abstract: The invention relates to the use of (1&agr;.2&bgr;,4&bgr;.5&agr;.7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4] nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation.

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.

Abstract: The present invention relates to new dihydropteridinones of the formula (I) 1

Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors, processes for preparing them and their use in the treatment of respiratory tract diseases.

Abstract: The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.

Abstract: The present invention relates to a process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines of formula I, wherein R1 to R4 have the meanings given in claim 1, as well as new intermediate products which are involved in this process.

Abstract: The present invention relates to new substituted salicylic acid salts of salmeterol, processes for preparing them and their use

Abstract: The present invention relates to atomizers for administering liquids to the cornea or conjunctiva of the eye, special eye adapters for atomizers and the use of atomizers for ophthalmological administration. The atomizers according to the invention are free from propellant gas and have an energy reservoir for supplying the energy needed for the atomization process.

Abstract: The present invention relates to a new atomiser for nasal or oral application of a medicinal-pharmaceutical aerosol, wherein the active ingredient formulation is always kept under sterile conditions. It is preferred that moisturisers, medicaments and/or wound healing agents are sprayed from the atomiser into the nose or the mouth.

Abstract: A pharmaceutical composition comprising:

Abstract: A process for preparing a compound of formula 1 1

Abstract: The invention relates to new compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, X and Ar1 have the meanings given in the specification, as well as the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin) antagonists.

Abstract: The invention relates to a process for preparing a compound of formula (I) wherein a compound of formula (II), wherein R1 denotes chlorine, bromine, iodine, —O—COCH3, tosylate or mesylate, is reacted with a compound of formula (III),  optionally in a suitable diluent and/or in the presence of a suitable added reagent or catalyst, the reaction being carried out in a temperature range from 20 to 80° C.

Abstract: A method for crystallizing a substance, especially an inhalable medicament, comprising the following steps: (a) dissolving said substance in a solvent, to produce a solution of said substance, (b) producing a segmented stream which consists of alternating segments of said solution of the substance and of a transport medium, (c) introducing said segmented stream into the first end of a retention stretch, which retention stretch has a first end and a second end, so that said segmented stream passes from said first end to said second end of said retention stretch, and exits from the second end of the retention stretch, (d) cooling the retention stretch, to thereby bring about crystallization of the substance in the segments of solution, in the segmented stream, as said segmented stream passes through the retention stretch, and (e) separating the crystals of material from the segmented stream as it exits from the second end of the retention stretch.

Abstract: The present application relates to new carboxylic acid amides of general formula wherein A, B and R1 to R3 are defined as in claim 1, processes for preparing them, pharmaceutical compositions containing these compounds and the use thereof and their preparation.

Abstract: A method of treating urinary incontinence in a patient in need thereof, the method comprising administering to the patient an effective amount of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol or a pharmacologically acceptable salt thereof, and pharmaceutical compositions.